Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Drug patents …
… from Kazakhstan to Kalamazoo
Find generic entry opportunities
Anticipate generic drug launch
Manage your formulary budget
Proactively manage your pharmacy inventory
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||MICROBIAL REDUCTION OF THIADIAZOLES|
|Abstract:||Process is described for reducing a 3-substituted-4-(3-amino-2-oxopropoxy)-1,2,5-thiadiazole chemically with sodium borohydride or aluminum alkoxide or by use of a bacterial, actinomycetales or fungal reductase to provide a 3-substituted-4-(3-amino-2-hydroxypropoxy)-1,2,5-thiadiazole that exhibits .beta.-adrenergic blocking properties and therefore useful, inter alia, in treatment of angina pectoris.|
|Inventor(s):||Weinstock; Leonard M. (Rocky Hill, NJ), Tull; Roger J. (Metuchen, NJ), Mulvey; Dennis M. (Iselin, NJ)|
|Assignee:||Charles E. Frosst & Co. (N/A)|
|Filing Date:||Apr 21, 1969|
|Claims:||1. A process wherein the ketonic function of a 3-X-4-[3-(Y-amino)-2-oxopropoxy]-1,2,5-thiadiazole is reduced which comprises incubating said thiadiazole with a reductase producing micro-organism selected from Clostridium butylicum, C. lentoputrescens, Escherichia coli, E. freundii, Aerobacter aerogenes, Mycobacterium lacticola, Bacillus megaterium, Corynebacterium simplex, Salmonella paratyphi, Leuconostoc mesenteroides, Acetobacter ascendens and Lactobacillus delbrueckii, Streptomyces lavendulae, S. coelicolor, Saccharomyces Cerevisiae, Geotrichum candidum, Curvularia falcata and C. lunata to provide 3-X-4-[3-(Y-amino)-2-hydroxypropoxy]-1,2,5-thiadiazole wherein in each of the foregoing compounds X is selected from chloro, lower alkyl, lower alkoxy, phenyl, benzyl, morpholino, piperidyl, hydroxypiperidyl and N-lower alkylpiperazinyl and Y is selected from lower alkyl and hydroxy-lower alkyl. |
2. A process as claimed in claim 1 wherein 3-morpholino-4-(3-tert-butylamino-2-oxopropoxy)-1,2,5-thiadiazole is employed as the starting ketone.
3. A process as claimed in claim 2 wherein the starting ketone is reduced by incubation in a culture medium containing Saccharomyces Cerevisiae.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.